{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"062-263-223-539-649","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"062-263-223-539-649","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11616,"type":"PATENT","title":"Case Western Reserve University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4001,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8291,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: weste* reser* AND Univ*
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2737
Search Applicants and Owners separately: weste* reser* AND Univ*
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2737
assaying a sample obtained from a patient for the presence of methylation within a nucleotide sequence as set forth in SEQ ID NO: 2 or fragments thereof;\n
wherein methylation of said nucleotide sequence is indicative of a vimentin-associated proliferative disorder; and\n
wherein said vimentin-associated proliferative disorder is a gastro-intestinal neoplasia."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the bodily fluid is obtained from a subject suspected of having or is known to have a vimentin-associated proliferative disorder."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, comprising assaying for the presence of methylation of the vimentin sequence of SEQ ID NO: 45."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, comprising assaying for the presence of methylation of a vimentin sequence selected from the group consisting of: SEQ ID NOs: 40-44."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the assay is methylation-specific PCR."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, comprising:\n
a) treating DNA from the sample with a compound that converts non-methylated cytosine bases in the DNA to a different base;\n
b) amplifying a region of the compound converted vimentin nucleotide sequence with a forward primer and a reverse primer; and\n
c) analyzing the methylation patterns of said vimentin nucleotide sequences."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, comprising:\n
a) treating DNA from the sample with a compound that converts non-methylated cytosine bases in the DNA to a different base;\n
b) amplifying a region of the compound converted vimentin nucleotide sequence with a forward primer and a reverse primer; and\n
c) detecting the presence and/or amount of the amplified product."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein the forward primers are selected from the group consisting of: SEQ ID NOs: 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 37, 38, 39, and the forward primers listed in FIG. 35."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein the reverse primers are selected from the group consisting of: SEQ ID NOs: 15, 17, 18, 20, 22, 24, 26, 28, 30, 32, 34, 35, 36, and the reverse primers listed in FIG. 35."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein the primer is selected from the group consisting of: MSP29, MSP47, and MSP50."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein the compound used to treat DNA is a bisulfite compound."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the assay comprises using a methylation-specific restriction enzyme."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein said methylation-specific restriction enzyme is selected from the group consisting of: HpaII, Smal, SacII, EagI, MspI, BstUI, and BssHII."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, further comprising a pair of primers selected from the group consisting of: SEQ ID NOs: 8-13, and the primers listed in FIG. 35."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a vimentin-associated proliferative disorder in a subject, comprising detecting vimentin protein or nucleic acid expression in a sample from the subject, wherein said vimentin-associated disorder is a gastro-intestinal neoplasia, and wherein the expression of vimentin protein or nucleic acid in said sample is indicative of an increased risk of vimentin-associated proliferative disorder in said subject."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 16, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the bodily fluid is from a subject suspected of having or known to have a vimentin-associated proliferative disorder."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 16, wherein the vimentin protein is detected by immunoassays."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A method for monitoring over time a vimentin-associated proliferative disorder comprising:\n
a) detecting the methylation status of a vimentin nucleotide sequence in a sample from a subject for a first time; and\n
b) detecting the methylation status of the vimentin nucleotide sequence in a sample from the same subject at a later time;\n
wherein absence of methylation in the vimentin nucleotide sequence taken at a later time and the presence of methylation in the vimentin nucleotide sequence taken at the first time is indicative of regression of the proliferative disorder;\n
wherein presence of methylation in the vimentin nucleotide sequence taken at a later time and the absence of methylation in the vimentin nucleotide sequence taken at the first time is indicative of progression of the proliferative disorder\n
wherein said vimentin-associated disorder is a gastro-intestinal neoplasia."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 20, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the sample is derived from a tissue."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the tissue sample is obtained from a subject suspected of having or is known to have a vimentin-associated proliferative disorder."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 16, wherein the sample is derived from a tissue."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 24, wherein the tissue sample is obtained from a subject suspected of having or is known to have a vimentin-associated proliferative disorder."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 20, wherein the sample is derived from a tissue."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the tissue sample is obtained from a subject suspected of having or is known to have a vimentin-associated proliferative disorder."],"number":27,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}